我如何管理套细胞淋巴瘤:惰性与侵袭性疾病
套细胞淋巴瘤(MCL)临床病程异质,惰性与侵袭性亚型已被认识。惰性MCL常表现为白血病样、SOX11阴性、Ki-67低;侵袭性MCL表现为快速广泛淋巴结肿大、结外受累、母细胞样或多形性组织学和高Ki-67,TP53异常对生存有明确负面影响。随着靶向新药和细胞治疗可及性增加,治疗格局不断演变。本综述描述两亚型的临床表现、生物学因素和具体管理考虑,并讨论当前和未来可能有助于走向更个体化方法的证据。
要点
- 惰性MCL常以白血病样表现、SOX11阴性和低Ki-67为特征。
- 侵袭性MCL表现为快速广泛淋巴结肿大、结外受累、母细胞样或多形性组织学和高Ki-67。
- 侵袭性MCL中TP53异常对生存有明确负面影响。
核心结论
- 惰性和侵袭性MCL亚型在临床表现、生物学因素和管理考虑上不同,靶向新药和细胞治疗可能帮助走向更个体化方法。
研究设计与样本
- 本综述描述惰性和侵袭性MCL的临床表现、生物学因素和具体管理考虑,并讨论当前和未来证据。
主要发现
- 惰性MCL常表现为白血病样、SOX11阴性和低增殖指数(Ki-67)。
- 侵袭性MCL以快速起病的广泛淋巴结肿大、结外受累、母细胞样或多形性组织学和高Ki-67为特征。
- 侵袭性MCL中TP53异常对生存有明确负面影响。
- 直到最近,试验未分别针对这些特定亚型。
局限性
- 直到最近,试验未分别针对惰性和侵袭性MCL特定亚型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma with a variable clinical course and historically poor prognosis. Management is challenging in part due to the heterogeneity of the disease course, with indolent and aggressive subtypes now well recognised. Indolent MCL is often characterised by a leukaemic presentation, SOX11 negativity and low proliferation index (Ki-67). Aggressive MCL is characterised by rapid onset widespread lymphadenopathy, extra-nodal involvement, blastoid or pleomorphic histology and high Ki-67. Tumour protein p53 (TP53) aberrations in aggressive MCL are recognised with clear negative impact on survival. Until recently, trials have not addressed these specific subtypes separately. With the increasing availability of targeted novel agents and cellular therapies, the treatment landscape is constantly evolving. In this review, we describe the clinical presentation, biological factors, and specific management considerations of both indolent and aggressive MCL and discuss current and potential future evidence which may help move to a more personalised approach.
引用
- Wilson MR, Barrett A, Cheah CY, et al. How I manage mantle cell lymphoma: indolent versus aggressive disease. Br J Haematol. 2023. PMID: 36807902. doi:10.1111/bjh.18697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。